



Treatment of Refractory Glomerular Diseases: Challenges and Solutions

Guest Editor:

Dr. Kouichi Hirayama

Department of Nephrology,
Tokyo Medical University,
Inashiki, Ibaraki, Japan

Deadline for manuscript
submissions:

closed (20 November 2023)

Message from the Guest Editor

Dear Colleagues,

Glomerular diseases other than diabetic nephropathy account for approximately 25% of chronic kidney disease (CKD) patients worldwide. Given the long duration of glomerular disease and the complications and prognosis associated with underlying disease and treatment, it is critical to optimize management to control and prevent progressive kidney disease. Recently, the KDIGO 2021 clinical practice guidelines for the management of glomerular disease were published and are expected to improve the prognosis and complications of glomerular disease. However, the treatment of glomerular disease still primarily consists of corticosteroids with or without several immunosuppressants, and there are only a few established treatments for the molecules involved in onset and progression, such as biological agents.

This issue focuses on primary glomerular diseases (idiopathic nephrotic syndrome, membranous nephropathy, IgA nephropathy, etc.), secondary glomerular diseases other than diabetic nephropathy (IgA vasculitis, lupus nephritis, ANCA-associated vasculitis, etc.) and hereditary glomerular disorders (Alport syndrome, Fabry disease, etc.).

Dr. Kouichi Hirayama
Guest Editor





medicina

IMPACT
FACTOR
2.6

Indexed in:
PubMed

CITESCORE
3.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian
University of Health Sciences,
Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*General Medicine*)

Contact Us

Medicina
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/medicina
medicina@mdpi.com